期刊文献+

补肾祛风通络方联合氨甲蝶呤治疗老年类风湿关节炎患者的效果

Effects of Bushen Qufeng Tongluo decoction combined with Methotrexate in treatment of elderly patients with rheumatoid arthritis
下载PDF
导出
摘要 目的:观察补肾祛风通络方联合氨甲蝶呤治疗老年类风湿关节炎患者的效果。方法:选取2019年5月至2021年5月该院收治的90例老年类风湿性关节炎患者进行前瞻性研究,按随机数字表法将其分为观察组与对照组各45例。对照组给予氨甲蝶呤治疗,观察组在对照组基础上联合补肾祛风通络方治疗,比较两组临床疗效、治疗前后中医证候积分、临床症状和不良反应发生率。结果:观察组治疗总有效率为95.56%(43/45),高于对照组的80.00%(36/45),差异有统计学意义(P<0.05);两组中医证候积分均低于治疗前,且观察组低于对照组,差异统计学意义(P<0.05);两组关节肿胀个数、关节压痛个数均少于治疗前,且观察组少于对照组,两组晨僵时间均短于治疗前,且观察组短于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:补肾祛风通络方联合氨甲蝶呤治疗老年类风湿关节炎患者可提高治疗总有效率,降低中医证候积分,加快症状缓解,其效果优于单纯氨甲蝶呤治疗。 Objective: To observe effects of Bushen Qufeng Tongluo decoction combined with Methotrexate in treatment of elderly patients with rheumatoid arthritis. Methods: A retrospective study was conducted on the clinical data of 90 elderly patients with rheumatoid arthritis admitted to this hospital from May 2019 to May 2021. They were divided into observation group and control group according to the random number table method, 45cases in each. The control group was treated with Methotrexate tablets, while the observation group was treated with Bushen Qufeng Tongluo decoction on the basis of that of the control group. The clinical efficacy, the TCM syndrome scores before and after the treatment, the levels of clinical symptom indexes,and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate of treatment in the observation group was 93.33 %(42/45), which was higher than 80.00%(36/45) in the control group, and the difference was statistically significant(P<0.05). The TCM syndrome scores of the two groups were lower than those before the treatment, those of the observation group were lower than those of the control group, and the difference was statistically significant(P<0.05). The numbers of joint swelling and joint tenderness in the two groups were lower than those before the treatment, and those of the observation group was lower than those of the control group;the morning stiffness time of the two groups were shorter than those before the treatment, and that of the observation group was shorter than that of the control group;and the differences were statistically significant(P<0.05).However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Bushen Qufeng Tongluo decoction combined with Methotrexate in the treatment of the elderly patients with rheumatoid arthritis can improve the total effective rate, reduce the TCM syndrome score and improve the levels of clinical symptoms. Moreover, it is superior to single Methotrexate tablets treatment.
作者 薛会芳 XUE Huifang(Department of Renal,Rheumatism,Endocrinology and Geriatrics of Yuxi Jianhe Hospital,Nanyang 474550 Henan,China)
出处 《中国民康医学》 2023年第1期106-108,共3页 Medical Journal of Chinese People’s Health
关键词 老年 类风湿关节炎 补肾祛风通络方 中医证候积分 氨甲蝶呤 Elderly Rheumatoid arthritis Bushen Qufeng Tongluo decoction TCM syndrome score Methotrexate
  • 相关文献

参考文献12

二级参考文献102

  • 1唐黎明,张素慧,宁炼.复方青风藤胶囊的主要药效学研究[J].中国实验方剂学杂志,2007,13(9):50-53. 被引量:12
  • 2陈灏珠.实用内科学[M]12版.北京:人民卫生出版社,2005.1746-1750.
  • 3O'Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two- year randomized, double-blind trial [ J ]. Arthritis Rheum, 2013,65 (8) : 1985-1994.
  • 4Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid ar- thritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update [ J ]. Ann Rheum Dis, 2014,73 (3) :492-509.
  • 5Pincus T, Gibson KA, Castrejon I. Update on metho- trexate as the anchor drug for rheumatoid arthritis [ J ]. Bull Hosp Jt Dis, (2013), 2013,71 Suppl 1 :S9-19.
  • 6Malik F, Ranganathan P. Methotrexate pharmacoge- netics in rheumatoid arthritis: a status report [ J ]. Pharmacogenomics, 2013,14 ( 3 ) :305-314.
  • 7Umicevic MM, Coenen MJ. Pharmacogenetics of dis- ease-modifying antirheumatic drugs in rheumatoid ar- thritis : towards personalized medicine [ J ]. Pharmacog- enomics, 2013,14 (4) :425-444.
  • 8Dervieux T, Furst D, Lein DO, et al. Pharmacogenet- ic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis trea- ted with methotrexate: results of a muhicentred cross sectional observational study [ J ]. Ann Rheum Dis, 2005,64(8) :1180-1185.
  • 9Romao VC, Canhao H, Fonseca JE. Old drugs, old problems: where do we stand in prediction of rheuma- toid arthritis responsiveness to methotrexate and other synthetic DMARDs[J] ? BMC Med, 2013,11:17.
  • 10Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Lack of correlation between pharmaeokinetics and effi- cacy of low dose methotrexate in patients with rheuma- toid arthritis [ J ]. J Rheumatol, 1995,22 (5) : 844- 849.

共引文献207

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部